May 17, 2023 / 02:30PM GMT
Brian Abrahams - RBC Capital Markets - Analyst
I'm Brian Abrahams, one of the senior biotech analysts here at RBC Capital Markets. Our next presenting company is Intra-Cellular Therapies represented by their CEO, Sharon Mates. Sharon, thanks again for joining us.
Sharon Mates - Intra-Cellular Therapies, Inc. - Founder, Chairman & CEO
Thanks for having me.
Brian Abrahams - RBC Capital Markets - Analyst
So maybe just to kick off on CAPLYTA. I would love to hear more about what you're hearing on the ground from physicians and patients across the different marketed indications with respect to CAPLYTA's profile, overall receptivity, and how they're using the drug in practice.
Sharon Mates - Intra-Cellular Therapies, Inc. - Founder, Chairman & CEO
Sure. So before we start with our Q&A, it's important that I tell you that today, I will be making forward-looking statements under the Private Securities Litigation Reform Act of 1995. Our actual results may differ, and I
Intra-Cellular Therapies Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 17, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers